The gist: Patients with intermediate- or high-risk prostate cancer who are prescribed treatment with leuprolide acetate before prostatectomy may benefit more if they also take abiraterone acetate (aka Zytiga).
“In a phase II study reported in the Journal of Clinical Oncology, Taplin et al found that the addition of neoadjuvant abiraterone acetate (Zytiga) to the luteinizing hormone–releasing hormone (LHRH) agonist leuprolide acetate resulted in greater suppression of intraprostatic androgens in patients with intermediate- or high-risk localized prostate cancer.
“In the study, 58 patients were randomly assigned to receive abiraterone plus leuprolide (n = 30) or leuprolide alone (n = 28) for 12 weeks followed by prostate biopsy. All patients then received 12 weeks of abiraterone plus leuprolide and underwent radical prostatectomy…
“The investigators concluded: ‘LHRH [agonist] plus [abiraterone acetate] treatment suppresses tissue androgens more effectively than LHRH [agonist] alone. Intensive intratumoral androgen suppression with LHRH [agonist] plus [abiraterone acetate] before prostatectomy for localized high-risk [prostate cancer] may reduce tumor burden.’ “